U.S. FDA Expands Simulations Plus Software Licenses

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (AMEX:SLP), a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Food and Drug Administration for additional licenses for the Company’s GastroPlus™ simulation software and new licenses for the Company’s DDDPlus™ software as well. DDDPlus is the world’s only in vitro dissolution software for the formulation scientist.

MORE ON THIS TOPIC